Quadrant Capital Group LLC Atea Pharmaceuticals, Inc. Transaction History

Quadrant Capital Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $985 - $1,454	319 New	319 $1,000
Q1 2023 May 11, 2023	BUY	$3.0 - $4.97 $174 - $288	58 New	58 $0
Q3 2022 Nov 10, 2022	SELL	$5.49 - $8.79 $236 - $377	-43 Reduced 33.08%	87 $0
Q2 2022 Aug 09, 2022	BUY	$5.33 - $8.18 $692 - $1,063	130 New	130 $1,000
Q1 2022 May 06, 2022	SELL	$5.5 - $9.19 $253 - $422	-46 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$7.67 - $44.59 $168 - $980	22 Added 91.67%	46 $0
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $511 - $841	24 New	24 $1,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $275M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.